Guardant Health, Inc. announced a strategic collaboration with Pfizer, Inc. to support the development and commercialization of Pfizer’s oncology portfolio. This multi-year agreement will leverage Guardant’s Infinity smart liquid biopsy platform.
Under the collaboration, Guardant’s liquid biopsy tests will be utilized in Pfizer’s global clinical studies. The partnership aims to evaluate the clinical utility of circulating tumor DNA (ctDNA) levels as a surrogate endpoint for treatment response.
This collaboration provides critical clinical context to an extensive database of solid tumor cancer patients with multiple liquid biopsies. It allows biopharma collaborators to better interpret disease biology and identify drivers and timing of tumor evolution, as well as intrinsic and acquired resistance mechanisms.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.